The Interferons:Biological Effects, Mechanisms of Action, and Use in Multiple Sclerosis
Ann Neurol 37:7-15, Weinstock-Guttman,B.,et al, 1995
Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia:A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial
Ann Neurol 97:329-343, Simonyan,K.,et al, 2025
Posttransplant Anti-GABAA Receptor Antibody-Associated Autoimmune Encephalitis
Neurol 102:e209245, Togni,C.L.,et al, 2024
Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Cranial Cavernous Malformations
Stroke 49:1029-1035, Stapleton, C.J. & Barker, F.G., 2018
Review of the Neurological Implications of von Hippel-Lindau Disease
JAMA Neurol 75:620-627, Dornbos, D.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Investigations in GABA? Receptor Antibody-Associated Encephalitis
Neurol 88:1012-1020,1010, Spatola, M.,et al, 2017
Intracranial Dural Arteriovenous Fistulae
Stroke 48:1424-1431, Reynolds, M.R.,et al, 2017
Arteriovenous Malformations of the Brain
NEJM 376:1859-1866, Solomon, R.A. & Connolly, E.S., 2017
An Older Man with Memory Impairment and Convulsions
BMJ 358:J2824, Zhao, X.,et al, 2017
Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017
Effect of Radiosurgery Alone vs Radiosurgery with Whole Brain Radiation Therapy on Cognitive Function in Patients with 1 to 3 Brain Metastases
JAMA 316:401-409,393, Brown, P.D.,et al, 2016
Neurological Management of Von Hippel-Lindau Disease
Neurologist 21:73-78, Hodgson, T.S.,et al, 2016
A 52-year-old Man with Diplopia and Ataxia
Neurol 87:e140-e143, Bradshaw, M.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Dexamethasone & Supportive Care with or without Whole Brain Radiotherapy in Treating Patients with Non-Small Cell Lung Cancer with Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy (QUARTZ): Results from a Phase 3,Non-Inferiority, Randomised Trial
Lancet 388:2004-2014, Mulvenna, P.,et al, 2016
Intracranial Dural Arteriovenous Fistulae
Stroke 46:2017-2025, Miller, T.R. & Gandhi, D., 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Early Radiosurgery Provides Superior Pain Relief for Trigeminal Neuralgia Patients
Neurol 85:2159-2165, Mousavi, S.H.,et al, 2015
Cerebral Palsy
Lancet 383:1240-1248, Colver, A.,et al, 2014
Long-Term Outcome of 106 Consecutive Pediatric Ruptured Brain Arteriovenous Malformations After Combined Treatment
Stroke 45:1664-1671, Blauwblomme, T.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Encephalitis and GABAb Receptor Antibodies
Neurol 81:1500-1506, H�ftberger, R.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Radiosurgery for Unruptured Cerebral Arteriovenous Malformations
Neurol 78:1292-1298, Yang,S.Y.,et al, 2012
Treatment of ?-Aminobutyric Acid� Receptor-Antibody Autoimmune Encephalitis with Oral Corticosteroids
Arch Neurol 69:1061-1063, Goldenholz, D.M.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Stereotactic Radiosurgery for the Management of Brain Metastases
NEJM 362:1119-1127, Suh,J.H., 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009
Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008
Practice Parameter: The Diagnostic Evaluation and Treatment of Trigeminal Neuralgia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the AAN & EFNS
Neurol 71:1183-1190, Gronseth,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Narcolepsy With Cataplexy
Lancet 369:499-511, Dauvilliers,Y.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Arteriovenous Malformations of the Brain
NEJM 356:2704-2712, Friedlander,R.M., 2007
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007